Psoriasis Therapeutics in Asia-Pacific Markets to 2021

1
Psoriasis Therapeutics in Asia-Pacific Markets
to 2021
No. Pages 91
Published on May - 2015
2
.
Report Overview
About Psoriasis Therapeutics in Asia-Pacific
Markets to 2021 Research Beam added a report
Psoriasis Therapeutics in Asia-Pacific Markets
to 2021. Psoriasis Therapeutics in Asia-Pacific
Markets to 2021 - Advent of Novel Biologics and
Expanding Treatment Pool to Drive Growth. GBI
Research, the leading business intelligence
provider, has released its latest research,
Psoriasis Therapeutics in Asia-Pacific Markets to
2021 Advent of Novel Biologics and Expanding
Treatment Pool to Drive Growth, which provides
insights into psoriasis therapeutics in the
Asia-Pacific (APAC) market. For the purposes of
this report, APAC refers to the market in China,
India, Japan, and Australia only. The report
estimates the market size for 2014, along with
forecasts until 2021. It also covers disease
epidemiology, treatment algorithms, treatment use
patterns, in-depth analysis of pipeline
molecules, clinical trial failure rates, and
analysis of recent deals. It is built using data
and information sourced from proprietary
databases, primary and secondary research, and
in-house analysis carried out by GBI Research
team of industry experts. Get Full Details On
http//www.researchbeam.com/psoriasis-therapeutics
-in-asia-pacific-to-2021-advent-of-novel-biologics
-and-expanding-treatment-pool-to-drive-growth-mark
et
3
.
Report Overview
In 2014, the value of the psoriasis therapeutics
market in APAC amounted to an estimated 690m,
and it is forecast to grow at a Compound Annual
Growth Rate (CAGR) of 8.4 between 2014 and 2021
to reach 1.2 billion. The psoriasis treatment
landscape is a particularly complex one. More
than 80 of patients fall into the
mild-or-moderate category, for which the first
line of treatment is topical drugs, phototherapy,
or a combination. In the case of severe patients,
non-steroidal drugs such as methotrexate,
cyclosporine, and acitretin are practiced as
first-line treatment however, they come with
toxicity concerns and so cannot be prescribed for
long durations. Biologics such as TNF inhibitors
(adalimumab, etanercept, infliximab) and
ustekinumab are largely prescribed as second-line
therapy when none of the aforementioned options
provide the desired results. However, during the
forecast period, biologics are likely gain a
significant patient share due to healthcare plans
in APAC and awareness regarding the effectiveness
of biologics. Among the recently launched
biologics, Cosentyx (secukinumab) from Novartis
has shown better efficacy than Enbrel
(etanercept), and is a novel molecule that
targets Interluekin-17 (IL-7). Biocon India has
launched Alzumab (itolizumab), which is a
first-in-class novel molecule that targets CD6
protein.
4
.
Report Overview

• It is anticipated to be the leading biologic in
  India by the end of forecast period. Humira
  (adalimumab), Enbrel (etanercept), and Remicade
  (infliximab) are expected to lose their patent
  during the forecast period, but will be
  compensated for by biosimilar versions.
•  
• Scope
•  
• The report analyzes treatment use patterns,
  market characterization, the pipeline, and key
  licensing and co-development deals for psoriasis
  in the APAC markets of China, India, Japan, and
  Australia. The report includes
• A brief introduction to psoriasis, including
  pathophysiology, etiology, diagnosis, and
  treatment algorithms
• In-depth analysis of currently marketed drugs,
  including analysis of safety, efficacy, treatment
  patterns, and strengths/weaknesses, along with a
  heat map comparing them in terms of safety and
  efficacy
• A comprehensive review of the pipeline for
  psoriasis, including individual analysis of a
  number of late-stage pipeline drugs likely to
  enter the market during the forecast period the
  pipeline is further analyzed on the basis of
  phase distribution, molecule type, program type,
  mechanism of action, and molecular target

5
Report Overview

• Additional in-depth analysis of pipeline drug
  clinical trials by phase, trial size, trial
  duration, and program failure rate for each
  molecule type
• Multi-scenario forecast data for the market to
  2021, taking into account how it might be
  affected by the introduction of new drugs, the
  expiry of key patents on current drugs, and
  changes in disease epidemiology across the key
  developed markets
• Discussion of the drivers of and barriers to
  market growth
• In-depth analysis of all licensing and
  co-development deals that have occurred in the
  psoriasis market since 2006
• Reasons to buy
•  
• The report will enhance your decision-making
  capability by allowing you to -
• Understand the psoriasis pipeline and the factors
  that indicate that it is becoming more innovative
• Analyze detailed profiles for promising pipeline
  products and gain insights into how they are
  likely to compete in the market and who their
  main competitors will be
• Follow the trends in psoriasis clinical trial
  size and duration in relation to industry
  averages. etc.

6
Table Of Contents
1 Table of Contents 51.1 List of Tables 71.2
List of Figures 72 Introduction 92.1 Symptoms
102.1.1 Skin Manifestations 102.1.2
Psychological Impact 102.2 Etiology,
Co-morbidities and Risk Factors 102.2.1 Genetics
102.2.2 Psoriatic Arthritis 102.2.3 Mental
Health Disorders 102.2.4 Metabolic Syndrome,
Smoking, Diet and Alcohol Consumption 112.2.5
Infections 112.2.6 Kaebner Phenomenon 11
7
Table Of Contents
2.2.7 Other Immune-Mediated Diseases 122.3
Pathophysiology 122.4 Diagnosis 122.5
Epidemiology 132.6 Treatment and Management
142.6.1 Pharmacological Therapies 152.6.2
Non-pharmacological Therapies 162.6.3
Combination and Rotational Therapies 162.6.4
Quality of Life Assessments 16 2.6.5 Summary 173
Marketed Products 183.1 Overview 183.2
Methotrexate-Based Products 183.3
Sandimmune/Neoral (cyclosporine/modified
cyclosporin) â Novartis 19
8
Table Of Contents
3.4 Humira (adalimumab) â AbbVie 203.5 Enbrel
(etanercept) â Amgen 223.6 Remicade
(infliximab) â Janssen Biotech 243.7 Stelara
(ustekinumab) â Janssen Biotech 25 3.8
Comparative Efficacy and Safety 274 Psoriasis
Market to 2021 â Pipeline Products 294.1
Overview 294.2 Overall Pipeline 294.3 Pipeline
Analysis by Molecule Type 314.4 Pipeline
Analysis by Molecular Target 32Enquiry about
this report _at_ http//www.researchbeam.com/psoriasi
s-therapeutics-in-asia-pacific-to-2021-advent-of-n
ovel-biologics-and-expanding-treatment-pool-to-dri
ve-growth-market/enquire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/psoriasis-therapeutics
-in-asia-pacific-to-2021-advent-of-novel-biologics
-and-expanding-treatment-pool-to-drive-growth-mark
et
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com